🎉 M&A multiples are live!
Check it out!

Vivoryon Therapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for Vivoryon Therapeutics and similar public comparables like Armata Pharmaceuticals, Protalix, and Pharming.

Vivoryon Therapeutics Overview

About Vivoryon Therapeutics

Vivoryon Therapeutics NV is a Germany-based biopharmaceutical company engaged in the activities of research and development, preclinical and clinical trials. It is focused on the development of therapeutic products for the treatment of Alzheimer's disease and cancer. The company's pipeline products include PQ912 and  PQ1565. Geographically, the majority is from Greater China.


Founded

1997

HQ

Netherlands
Employees

17

Website

vivoryon.com

Financials

LTM Revenue n/a

LTM EBITDA -$22.6M

EV

$37.0M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Vivoryon Therapeutics Financials

Vivoryon Therapeutics has a last 12-month revenue of n/a and a last 12-month EBITDA of -$22.6M.

In the most recent fiscal year, Vivoryon Therapeutics achieved revenue of -$4.0M and an EBITDA of -$31.0M.

Vivoryon Therapeutics expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Vivoryon Therapeutics valuation multiples based on analyst estimates

Vivoryon Therapeutics P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue -$4.0M n/a XXX XXX XXX
Gross Profit $10.0M n/a XXX XXX XXX
Gross Margin -254% NaN% XXX XXX XXX
EBITDA -$31.0M -$23.2M XXX XXX XXX
EBITDA Margin 783% -Infinity% XXX XXX XXX
Net Profit -$13.8M -$30.7M XXX XXX XXX
Net Margin 350% -Infinity% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Vivoryon Therapeutics Stock Performance

As of March 14, 2025, Vivoryon Therapeutics's stock price is EUR 2 (or $2).

Vivoryon Therapeutics has current market cap of EUR 49.2M (or $53.7M), and EV of EUR 33.9M (or $37.0M).

See Vivoryon Therapeutics trading valuation data

Vivoryon Therapeutics Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$37.0M $53.7M XXX XXX XXX XXX $-1.02

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Vivoryon Therapeutics Valuation Multiples

As of March 14, 2025, Vivoryon Therapeutics has market cap of $53.7M and EV of $37.0M.

Vivoryon Therapeutics's trades at n/a LTM EV/Revenue multiple, and -1.6x LTM EBITDA.

Analysts estimate Vivoryon Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Vivoryon Therapeutics and 10K+ public comps

Vivoryon Therapeutics Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $37.0M XXX XXX XXX
EV/Revenue n/a XXX XXX XXX
EV/EBITDA -1.6x XXX XXX XXX
P/E -2.3x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -1.4x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Vivoryon Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Vivoryon Therapeutics Valuation Multiples

Vivoryon Therapeutics's NTM/LTM revenue growth is n/a

Vivoryon Therapeutics's revenue per employee for the last fiscal year averaged -$0.2M, while opex per employee averaged $1.7M for the same period.

Over next 12 months, Vivoryon Therapeutics's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Vivoryon Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Vivoryon Therapeutics and other 10K+ public comps

Vivoryon Therapeutics Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth -100% XXX XXX XXX XXX
EBITDA Margin n/a XXX XXX XXX XXX
EBITDA Growth -25% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee -$0.2M XXX XXX XXX XXX
Opex per Employee $1.7M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue -90% XXX XXX XXX XXX
R&D Expenses to Revenue -487% XXX XXX XXX XXX
Opex to Revenue -710% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Vivoryon Therapeutics Public Comps

See public comps and valuation multiples for Biopharmaceuticals and Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Armata Pharmaceuticals XXX XXX XXX XXX XXX XXX
Protalix XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Vivoryon Therapeutics M&A and Investment Activity

Vivoryon Therapeutics acquired  XXX companies to date.

Last acquisition by Vivoryon Therapeutics was  XXXXXXXX, XXXXX XXXXX XXXXXX . Vivoryon Therapeutics acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Vivoryon Therapeutics

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Vivoryon Therapeutics

When was Vivoryon Therapeutics founded? Vivoryon Therapeutics was founded in 1997.
Where is Vivoryon Therapeutics headquartered? Vivoryon Therapeutics is headquartered in Netherlands.
How many employees does Vivoryon Therapeutics have? As of today, Vivoryon Therapeutics has 17 employees.
Who is the CEO of Vivoryon Therapeutics? Vivoryon Therapeutics's CEO is Dr. Ulrich Dauer.
Is Vivoryon Therapeutics publicy listed? Yes, Vivoryon Therapeutics is a public company listed on AMS.
What is the stock symbol of Vivoryon Therapeutics? Vivoryon Therapeutics trades under VVY ticker.
When did Vivoryon Therapeutics go public? Vivoryon Therapeutics went public in 2014.
Who are competitors of Vivoryon Therapeutics? Similar companies to Vivoryon Therapeutics include e.g. Julphar, Galapagos, Pharming, Armata Pharmaceuticals.
What is the current market cap of Vivoryon Therapeutics? Vivoryon Therapeutics's current market cap is $53.7M
What is the current EBITDA of Vivoryon Therapeutics? Vivoryon Therapeutics's last 12-month EBITDA is -$22.6M.
What is the current EV/EBITDA multiple of Vivoryon Therapeutics? Current EBITDA multiple of Vivoryon Therapeutics is -1.6x.
Is Vivoryon Therapeutics profitable? Yes, Vivoryon Therapeutics is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.